concentrations

[키워드] 1:1 24 hour 24 hours Acute kidney injury Acute respiratory failure Administered Analysis Antibiotics arterial arterial pressure Bacterial Berlin blinded Blinding block blocks Blood C-reactive protein C-reactive protein (CRP catecholamine cause center Chain Reaction Charité clinical Clinical course Clinical practice clinical trials clinically clinician comparator concentrations condition conducted contraindication COVID-19 COVID-19 patient COVID-19 patients Critical care Critically ill critically ill COVID-19 patients Critically ill patient critically ill patients cytokine Cytokine storm Cytokines Cytosorb CytoSorb® data set death defined dissemination dose element elevated Endpoint extracorporeal cytokine elimination feasibility Filter Formal Germany Hemodynamics hospital discharge Hospitalization hospitalized patient hospitalized patients hyperinflammation Hyperinflammatory ICU-treatment ICUs IIb IL-6 IMPROVE Inc. Inclusion inclusion criteria indication intensive care unit intensive care units interleukin interleukin-6 intervention effect mean arterial pressure mechanical ventilation molecular weight Mortality multicenter New Norepinephrine number objective observational study occur Open-label other conditions outcome parallel group participant Patient patients PCR PCT performed phase pilot study polymerase chain polymerase chain reaction polystyrene positive pressure Prevent primary endpoint procalcitonin Proinflammatory cytokine proinflammatory cytokines protocol randomization Randomized Randomized controlled trial reason for receive recruited reducing Registered registry renal replacement therapy replacement therapy rescue Respiratory failure Safety Safety assessment Sample size SARS-CoV-2 secondary Secondary outcomes Shock shown Standard of care statistician status stratified Study design Study protocol Suspected therapy toxin Treatment Trial Trial registration USA vasoplegic shock Vasopressor vasopressors website
[DOI] 10.1186/s13063-020-04501-0 PMC 바로가기 [Article Type] Letter